abrdn Life Sciences Investors
HQL
80 hedge funds and large institutions have $80.4M invested in abrdn Life Sciences Investors in 2023 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 34 increasing their positions, 24 reducing their positions, and 8 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 24
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
8% more capital invested
Capital invested by funds: $74.4M → $80.4M (+$5.95M)
3.62% more ownership
Funds ownership: 20.97% → 24.59% (+3.6%)
3% more funds holding
Funds holding: 78 → 80 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSC
Logan Stone Capital
Chicago,
Illinois
|
+$2.23M |
| 2 |
RL
RPO LLC
Stamford,
Connecticut
|
+$1.85M |
| 3 |
SCM
Saba Capital Management
New York
|
+$1.77M |
| 4 |
CCP
Clough Capital Partners
Boston,
Massachusetts
|
+$1.72M |
| 5 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$1.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
-$1.8M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.26M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$716K |
| 4 |
Cohen & Steers
New York
|
-$395K |
| 5 |
JP Morgan Chase
New York
|
-$272K |
HQL Hedge Fund Activity: Q3 2023 in Review
80 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q3 2023, worth a combined $80.4M — up 8% from $74.4M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new HQL positions and 8 closed out — a net gain of 3 holders — while 34 added to existing stakes and 24 trimmed.
The largest buyer was Logan Stone Capital, adding an estimated $2.23M. The largest seller was Raymond James & Associates, cutting an estimated $1.8M.
- 80 institutional investors held abrdn Life Sciences Investors (HQL) as of Q3 2023, up from 78 in Q2 2023.
- Funds reported $80.4M of abrdn Life Sciences Investors stock for Q3 2023, up 8% quarter-over-quarter.
- 11 funds opened new abrdn Life Sciences Investors positions in Q3 2023 and 8 closed out, a net change of +3 holders.
- The largest abrdn Life Sciences Investors buyer in Q3 2023 was Logan Stone Capital, an estimated $2.23M added.
- The largest abrdn Life Sciences Investors seller in Q3 2023 was Raymond James & Associates, an estimated $1.8M sold.
Based on aggregated 13F filings for Q3 2023.